Ran Brosh
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Oncology top 2%
- Cancer-related Molecular Pathways
Papers in
-
- CRISPR and Genetic Engineering 12
- Genomics and Chromatin Dynamics 10
- Epigenetics and DNA Methylation 9
- RNA Research and Splicing 7
- Cancer-related gene regulation 6
- Pluripotent Stem Cells Research 5
- RNA Interference and Gene Delivery 5
- Oncology 16
- Cancer-related Molecular Pathways 13
- Co-authors
- Varda Rotter (27 shared papers)Noa Rivlin (6 shared papers)Moshe Oren (3 shared papers)Naomi Goldfinger (16 shared papers)Alina Molchadsky (8 shared papers)Shalom Madar (12 shared papers)Yosef Buganim (11 shared papers)Rachel Sarig (6 shared papers)
- Journals
- Carcinogenesis (4 papers)PLoS ONE (3 papers)Molecular Cell (2 papers)Nature (2 papers)Molecular Systems Biology (2 papers)
- Partner nations
- IsraelUnited StatesRussia
In The Last Decade
Ran Brosh
43 papers receiving 3.7k citations
Ran Brosh's Hit Papers
Peers
Comparison fields: 5 of 120
- Cancer Research 830
- Oncology 1.4k
- Molecular Biology 2.4k
- Biotechnology 229
- Aging 27
Countries citing papers authored by Ran Brosh
This map shows the geographic impact of Ran Brosh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ran Brosh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ran Brosh more than expected).
Fields of papers citing papers by Ran Brosh
This network shows the impact of papers produced by Ran Brosh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ran Brosh. The network helps show where Ran Brosh may publish in the future.
Co-authors
The 25 scholars most cited alongside Ran Brosh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | When mutants gain new powers: news from the mutant p53 field Hit paper breakdown → | 2009 | 887 |
| 2 | Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis Hit paper breakdown → | 2011 | 768 |
| 3 | 2012 | 209 | |
| 4 | 2010 | 133 | |
| 5 | 2008 | 132 | |
| 6 | 2010 | 130 | |
| 7 | 2004 | 119 | |
| 8 | 2011 | 90 | |
| 9 | 2020 | 79 | |
| 10 | 2009 | 72 | |
| 11 | 2008 | 70 | |
| 12 | 2010 | 64 | |
| 13 | 2005 | 64 | |
| 14 | 2007 | 61 | |
| 15 | 2009 | 59 | |
| 16 | 2012 | 58 | |
| 17 | 2008 | 50 | |
| 18 | 2007 | 49 | |
| 19 | 2010 | 49 | |
| 20 | 2012 | 44 |
About Ran Brosh
Ran Brosh is a scholar working on Molecular Biology, Oncology, Cancer Research, Genetics and Biotechnology, having authored 45 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (13 papers), CRISPR and Genetic Engineering (12 papers), Genomics and Chromatin Dynamics (10 papers), Epigenetics and DNA Methylation (9 papers), RNA Research and Splicing (7 papers), Cancer-related gene regulation (6 papers), Pluripotent Stem Cells Research (5 papers) and RNA Interference and Gene Delivery (5 papers). The work is most often cited by research in Cancer Research (830 citations), Oncology (1.4k citations), Molecular Biology (2.4k citations), Biotechnology (229 citations) and Aging (27 citations). Ran Brosh has collaborated with scholars based in Israel, United States and Russia. Frequent co-authors include Varda Rotter, Noa Rivlin, Moshe Oren, Naomi Goldfinger, Alina Molchadsky, Shalom Madar, Yosef Buganim, Rachel Sarig, Hilla Solomon and Ido Goldstein. Their work appears in journals such as Carcinogenesis, PLoS ONE, Molecular Cell, Nature and Molecular Systems Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.